immatics Announces Publication of IMA901 Cancer Vaccine Data in Nature Medicine: Immune Response Associates With Longer Survival
TUEBINGEN, Germany, July 29, 2012 /PRNewswire/ –
Paper highlights clinical and immunological activity of IMA901 in renal cell carcinoma
IMA901 is currently being evaluated in a pivotal phase 3 randomized study in patients
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing
advanced therapeutic vaccines that are active against cancer, today announced that key
data covering the scientific and clinical development of its lead cancer vaccine, IMA901,
have been published in Nature Medicine. The paper highlights that renal cell carcinoma
patients experience longer survival times when their immune system produces an immune
response to more than one of the peptides in IMA901, the first multi-peptide therapeutic
cancer vaccine for RCC.
IMA901 consists of 10 tumor-associated peptides (TUMAPs) confirmed to be naturally
presented on tumor cells in patients with renal cell carcinoma (RCC). immatics identified,
selected and validated the peptides in IMA901 using its proprietary XPRESIDENTTM platform,
which has enabled a uniquely rational approach to cancer vaccine development.
The Nature Medicine paper reports the findings of two clinical trials with IMA901 in
RCC patients. These results are the first showing that naturally presented TUMAPs are
clinically relevant in the development of cancer vaccines and can produce meaningful
outcomes. In contrast with a number of other cancer vaccine approaches, this research
demonstrates that patients who mount a broad anti-tumor immune response experience
In another key finding, the researchers identified two serum biomarkers which may help
to determine which patients are most likely to achieve an overall survival benefit in
future studies with IMA901. The current pivotal phase 3 trial with IMA901 aims to confirm
that these two biomarkers are predictive of improved overall survival.
Dr Harpreet Singh, immatics’ Chief Scientific Officer and corresponding author of the
publication, said: “Having these results published by Nature Medicine is recognition of
the rationale behind our development of IMA901 and our other pipeline products. When we
formed immatics we were clear that a rational approach to cancer vaccine development was
crucial for success. We have been rigorous in following a highly systematic process to
identify multiple relevant peptides from primary tumor tissues and then using
immunomonitoring and biomarkers to generate and advance IMA901. This journey has produced
several novel findings in the cancer immunotherapy field which we believe will advance the
development of cancer vaccines and could change the way the disease is managed and
Paul Higham, immatics’ Chief Executive Officer, said: “The potential of IMA901 to
extend survival times for patients with renal cancer while offering a very good side
effect profile is very exciting and offers the potential of real clinical benefit to
patients with RCC. Our results so far illustrate the power of our rational approach to
cancer vaccine development. We look forward to confirming the positive findings we have
generated when we report the results from our on-going pivotal phase 3 trial with IMA901.”
The work was performed in close collaboration with a large number of academic
institutions, foremost the University of Tuebingen, where the Department of Immunology ‘
led by Prof. Hans-Georg Rammensee, also the originator of the concept behind IMA901 and
co-founder of immatics ‘ and the Department of Urology ‘ led by Prof. Arnulf Stenzl,
also the Principal Investigator of both clinical trials described in this publication ‘
played a vital role.
About the publication
The Nature Medicine publication summarizes the results of two clinical trials with
IMA901 in a total of 96 RCC patients with a number of important clinical findings.
Firstly, these studies show that patients achieve better clinical benefit if they are
able to mount immune responses to multiple peptides in the IMA901 vaccine. This confirms
the hypothesis that a broad attack of the immune system on multiple targets simultaneously
Additionally, the study demonstrated in a randomized phase 2 trial that a single dose
of cyclophosphamide given prior to the first vaccination with IMA901 reduced numbers of
regulatory T cells and was associated with a better overall outcome after vaccination with
IMA901. Regulatory T cells are thought to counteract the anti-tumor response of cancer
The publication also describes the work to identify serum biomarkers to help predict
which patients could achieve an overall survival benefit in future studies with IMA901.
Through an analysis of over 300 potential biomarkers in pre-treatment samples from the
phase 2 study with IMA901, immatics identified two biomarkers, apolipoprotein A-1 and
chemokine (C-C motif) ligand 17, that could predict which patients are most likely to
achieve longer survival times with IMA901. The current pivotal phase 3 trial with IMA901
aims to validate that these two biomarkers are predictive of improved overall survival.
And finally, for the first time in RCC patients, the clinical relevance of certain
types of myeloid-derived suppressor cells, a novel type of regulatory cell counteracting
cancer immunotherapy, was described. Sunitinib, the standard first-line therapy in RCC
marketed by Pfizer, is combined in the ongoing phase 3 study with IMA901 to decrease
numbers of myeloid-derived suppressor cells.
IMA901 is a rationally designed cancer vaccine comprising 10 different
tumor-associated peptides (TUMAPs) that are found to be highly over-expressed in the
majority of patients suffering from RCC. IMA901 is a peptide-based vaccine with a stable,
off-the-shelf formulation and robust and easily scalable manufacturing. IMA901 has
completed phase 1 and 2 development in a total of 96 RCC patients and is currently being
developed in a pivotal, randomized controlled phase 3 study in combination with sunitinib.
immatics biotechnologies is a clinical-stage biopharmaceutical company developing
advanced therapeutic vaccines that are active against cancer. immatics’ lead product,
IMA901, is in a pivotal phase 3 study after completing a successful phase 2 trial in renal
cell carcinoma. immatics’ pipeline also includes IMA910, which has reported improved
overall survival data in patients with advanced colorectal cancer, and IMA950, which is in
phase 1 in patients with glioma.
immatics’ technology platform rapidly generates defined therapeutic cancer vaccines
which are based on multiple tumor-associated peptides (TUMAPs) with the ability to
specifically stimulate the immune system against cancer cells. These vaccines – comprising
multiple peptides confirmed to be naturally presented by real tumor tissue – offer the
prospect of greater effectiveness than existing therapeutic approaches combined with fewer
side effects. immatics’ products are ‘drug like’ with stable, off-the-shelf formulations
and robust easily scalable manufacturing.
immatics is based in Tuebingen and Martinsried (Munich), Germany.
For additional information on immatics please visit http://www.immatics.com or
Paul Higham, CEO Nikola Wiegeler, Assistant to the Management immatics biotechnologies GmbH Phone: +49-7071-5397-110 E-mail: firstname.lastname@example.org Citigate Dewe Rogerson David Dible / Chris Gardner / Sita Shah Phone: +44-207-638-9571 E-mail: email@example.com
1. “Multipeptide immune response to cancer vaccine IMA901 after single-dose
cyclophosphamide associates with longer patient survival,” Walter S., Weinschenk T. et al.
(2012) Nature Medicine. Published online: 29 July 2012